Who is sponsoring NCT01608698?

NCT01608698 is sponsored by Mahidol University.

What drugs are being tested in NCT01608698?

Interventions in NCT01608698: 30 mcg ethinylestradiol/2 mg chlormadinone acetate, 30 mcg ethinylestradiol/3 mg drospirenone.

What condition does NCT01608698 study?

NCT01608698 studies Body Weight Changes.

Is NCT01608698 still recruiting?

NCT01608698 is currently status unknown. Last updated 7 April 2015.

Last reviewed 2015-04-07 · How we verify

NCT01608698

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Comparison of Body Weight Changing and Side Effects Between Treatment With 30 mcg Ethinylestradiol/2 mg Chlormadinone Acetate (Belara®) and 30 mcg Ethinylestradiol/3 mg Drospirenone (Yasmin®): A Randomized Control Trial

Status unknown Phase 4 Last updated 7 April 2015

What this trial tests

Phase 4 trial testing 30 mcg ethinylestradiol/2 mg chlormadinone acetate in Body Weight Changes in 100 participants. Status unknown.

Timeline

1 June 2012

Primary endpoint
1 January 2016

1 February 2016

Quick facts

Lead sponsor	Mahidol University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	100
Start date	1 June 2012
Primary completion	1 January 2016
Estimated completion	1 February 2016
Sites	1 location across Thailand

Drugs / interventions tested

30 mcg ethinylestradiol/2 mg chlormadinone acetate — full drug profile →
30 mcg ethinylestradiol/3 mg drospirenone — full drug profile →

Conditions studied

Body Weight Changes — all drugs for Body Weight Changes →

Sponsor

Mahidol University

Who can join

Adults 19 to 45, female only, with Body Weight Changes. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

body weight change
Time frame: 6 month
Compare the body weight change during use of two OCP (30 mcg ethinylestradiol/2 mg chlormadinone acetate (Belara®) and 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin®)). By follow up at 3rd and final at 6th month of use.

Sponsor's own description

The purpose of this study is to evaluate different side effect in contraceptive use of two oral combined contraceptive pills (OCP)in combination of 30 mcg ethinylestradiol/2 mg chlormadinone acetate (Belara®) and 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin®), especially body weight change.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comparison of change in body weight between contraception containing 30-μg ethinylestradiol/2-mg chlormadinone acetate or 30-μg ethinylestradiol/3-mg drospirenone: a randomised controlled trial.
Wongwananuruk T, Panichyawat N, Panchalee T, Jirakittidul P, et al · · 2020 · cited 1× · PMID 31756117 · DOI 10.1080/13625187.2019.1688290

Verify or expand the search:

Other recruiting trials for Body Weight Changes

Currently open trials in the same condition.

NCT06464497 — Whole Foods for Teens: A Pilot Dietary Intervention to Reduce Body Adiposity in Adolescents With Obesity · NA · recruiting
NCT06777498 — The Precision Nutrition New York Study · NA · recruiting
NCT05644717 — Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD · Phase 4 · recruiting
NCT05220709 — Bio Impedance Monitoring as a Tool to Assess Fluid Status in the Pediatric Surgical Patient? (PedFluid Study) · NA · recruiting
NCT06534567 — Body Composition, Growth, and Maturation of Triathletes · recruiting

Other Mahidol University trials

Trials by the same sponsor.

NCT07568496 — Greater Occipital Nerve Block for Migraine With Medication Overuse Headache · NA · not yet recruiting
NCT07407400 — Lemborexant for Sleep and Delirium Prevention in Elderly ICU Patients · Phase 4 · not yet recruiting
NCT07378501 — Thai Version of the Pediatric Quality of Recovery Score (PedSQoR): Translation and Psychometric Validation Study · not yet recruiting
NCT07438301 — Septic Shock Hemodynamic Respond to Volume Resuscitation Versus Vasopressor Administration · not yet recruiting
NCT07390006 — Enabling Patient-Reported Outcomes Through Innovative Care - ACS (EPIC-ACS) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01608698 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mahidol University
Last refreshed: 7 April 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01608698.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing